SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo, Inc. Shifts 6 Early Drug Programs to India

February 8, 2011 | 
1 min read
Rediff -- Daiichi Sankyo, Japan's third-largest drug maker, has transferred six of its early drug discovery programmes in inflammatory and infectious diseases from its Japanese research & development (R&D) facilities to India.
Asia
Daiichi Sankyo
MORE ON THIS TOPIC
Close up shot red darts arrows in the target center on dark blue sky background. Business target or goal success and winner concept.
Lung cancer
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
July 15, 2026
 · 
2 min read
 · 
Michael Gibney
Businessman caring golden coins. Money saving, good investment, successful banker concept
Deals
Spero bets up to $1.1B for Innovent’s autoimmune antibody
July 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Business negotiation and cooperation vector concept. Symbol of a deal, handshake, success. Minimal design eps10 illustration.
Lung cancer
AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B
July 14, 2026
 · 
2 min read
 · 
Tristan Manalac
Close up shot red darts arrows in the target center on dark blue sky background. Business target or goal success and winner concept.
Antibody-drug conjugates
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
July 10, 2026
 · 
1 min read
 · 
Gabrielle Masson